Stability of Blood Eosinophil Count in Patients with COPD in the UK Clinical Practice Research Datalink

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 14, Issue 4, 2017, Pages 382-388

  Landis, Sarah H ^a   Suruki, Robert ^b   Hilton, Emma ^a   Compton, Chris ^a   Galwey, Nicholas W ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Biomarker stability; blood eosinophils; COPD; primary care

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DYSPNEA; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SMOKING; UNITED KINGDOM; BLOOD; EOSINOPHIL; LEUKOCYTE COUNT; PREDICTIVE VALUE; PRIMARY HEALTH CARE; REPRODUCIBILITY; TIME FACTOR; VERY ELDERLY;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; EOSINOPHILS; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; TIME FACTORS; UNITED KINGDOM;

EID: 85020188999     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412555.2017.1313827     Document Type: Article

References (24)

1. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in COPD:the Copenhagen General Population Study. Am J Respir Crit Care Med 2016; 193:965–974.
2. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease:a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3:435–442.
3. Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax 2016; 71:118–125.
4. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils:a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192:523–525.
5. Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids:a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016; 4:390–398.
6. Winkel P, Statland BE, Saunders AM, Osborn H, Kupperman H. Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers. Am J Clin Pathol 1981; 75:693–700.
7. Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, et al. Asthma outcomes:biomarkers. J Allergy Clin Immunol 2012; 129(3 Suppl):S9–S23.
8. Bestall JC, Paul EA, Garrod R, Garnham R, Jones P, Wedzicha J. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54:581–586.
9. Fleiss J. The Design and Analysis of Clinical Experiments. New York:John Wiley & Sons, 1986.
10. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27:822–832.
11. Salomaa V, Rasi V, Stengård J, Vahtera E, Pekkanen J, Vartiainen E, et al. Intra- and interindividual variability of hemostatic factors and traditional cardiovascular risk factors in a three-year follow-up. Thromb Haemost 1998; 79:969–974.
12. Alexander KS, Kazmierczak SC, Snyder CK, Oberdorf JA, Farrell DH. Prognostic utility of biochemical markers of cardiovascular risk:impact of biological variability. Clin Chem Lab Med 2013; 51:1875–1882.
13. Meigs JB, Nathan DM, Cupples LA, Wilson PW, Singer DE. Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. J Clin Epidemiol 1996; 49:411–417.
14. Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc 2014; 11:531–536.
15. Boorsma M, Lutter R, van de Pol MA, Out TA, Jansen HM, Jonkers RE. Repeatability of inflammatory parameters in induced sputum of COPD patients. COPD 2007; 4:321–329.
16. Beeh KM, Beier J, Kornmann O, Mander A, Buhl R. Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest 2003; 123:778–783.
17. Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease:a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186:48–55.
18. Balzano G, Stefanelli F, Iorio C, De Felice A, Melillo EM, Martucci M, et al. Eosinophilic inflammation in stable chronic obstructive pulmonary disease relationship with neutrophils and airway function. Am J Respir Crit Care Med 1999; 160:1486–1492.
19. Brightling CE, Monterio W, Green RH, Parker D, Morgan MD, Wardlaw AJ, et al. Induced sputum and other outcome measures in chronic obstructive pulmonary disease:safety and repeatability. Respir Med 2001; 95:999–1002.
20. Peleman RA, Rytilä PH, Kips JC, Joos GF, Pauwels RA. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J 1999; 13:839–843.
21. Kreindler JL, Watkins ML, Lettis S, Tal-Singer R, Locantore N. Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD. BMJ Open Respir Res 2016; 3:e000151.
22. Quint JK, Müllerova H, DiSantostefano RL, Forbes H, Eaton S, Hurst JR, Davis K, Smeeth L. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open 2014; 4:e005540.
23. Rothnie KJ, Müllerová H, Goss H, Chandan J, Quint JK. P223 Validity and interpretation of spirometry for patients in primary care. Thorax 2015; 70(Suppl 3):A188–A90.
24. Müllerová H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One 2014; 9:e85540.